Article thumbnail

Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA).

By Yeon Sook Kim, Sungmin Kiem, Hwan-Jung Yun, Sook In Jung, Won Sup Oh, Shin-Woo Kim, Kyong Ran Peck, Nam Yong Lee and Jae-Hoon Song


There have been conflicting data about the interactions between vancomycin and beta-lactam agents against Staphylococcus aureus strains with heterogeneous resistance to vancomycin. We evaluated the efficacy of these combinations against Mu 3 and heterogeneously vancomycin-resistant S. aureus (hetero-VRSA) strains which were isolated from Korean patients using a population analysis method. Antagonistic effects were observed when less than 1 g/mL of beta-lactam antibiotics was combined with vancomycin, whereas synergistic effects were noticed with more than 4 microgram/mL of beta-lactam antibiotics. The antagonistic effects at low concentrations of beta-lactams were most prominent at 2 microgram/mL of vancomycin, which were the vancomycin MICs of tested hetero-VRSA strains. This study showed the variable effects of vancomycin- beta-lactam combinations depending on the concentrations of beta-lactam antibiotics and this property could be used to develop screening methods for hetero-VRSA strains

Topics: Research Article
Publisher: Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis
  2. (2000). Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis
  3. (2002). Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea.
  4. (2001). Combination effect of vancomycin and -lactams against a Staphylococcus aureus strain, Mu 3, with heterogenous resistance to vancomycin. Antimicrob Agents Chemother
  5. (1999). Combinations of vancomycin and -lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother
  6. (1998). Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA
  7. (1998). Development of a medium (Mu 3) for detection of hetero-vancomycin resistant MRSA (hetero-VRSA).
  8. (1997). Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus Minnesota and North Dakota,
  9. (2002). Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin United States,
  10. (1997). Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin United States,
  11. (2002). Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus Pennsylvania,
  12. (1997). Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet
  13. (1999). Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus.
  14. (1998). First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet
  15. (1999). Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility.
  16. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
  17. (2000). Prevalence of Staphylococcus aureus with reduced susceptibility to vancomycin in a tertiary hospital.
  18. (2000). Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals.
  19. Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically,
  20. (1999). The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.
  21. (1999). The effects of vancomycin and -lactam antibiotics on vancomycin-resistant Staphylococcus aureus.
  22. (2000). Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob Agents Chemother
  23. (1990). Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother
  24. (1998). Vancomycin resistance in staphylococci. Drug Resist Updat
  25. (1998). Vancomycin-resistant Staphylococcus aureus. Lancet
  26. (2000). Vancomycinintermediate resistant S. aureus in Korea.